Stem/progenitor cells can be used to repair defects in the airway wall, resulting from e.g., tumors, trauma, tissue reactions following long-time intubations, or diseases that are associated with epithelial damage. Several potential sources of cells for airway epithelium have been identified. These can be divided into two groups. The first group consists of endogenous progenitor cells present in the respiratory tract. This group can be subdivided according to location into (a) a ductal cell type in the submucosal glands of the proximal trachea, (b) basal cells in the intercartilaginous zones of the lower trachea and bronchi, (c) variant Clara cells (Clara v -cells) in the bronchioles and (d) at the junctions between the bronchioles and the alveolar ducts, and (e) alveolar type II cells. This classification of progenitor cell niches is, however, controversial. The second group consists of exogenous stem cells derived from other tissues in the body. This second group can be subdivided into: (a) embryonic stem (ES) cells, induced pluripotent stem (iPS) cells, or amniotic fluid stem cells, (b) side-population cells from bone marrow or epithelial stem cells present in bone marrow or circulation and (c) fat-derived mesenchymal cells. Airway epithelial cells can be co-cultured in a system that includes a basal lamina equivalent, extracellular factors from mesenchymal fibroblasts, and in an air-liquid interface system. Recently, spheroid-based culture systems have been developed. Several clinical applications have been suggested: cystic fibrosis, acute respiratory distress syndrome, chronic obstructive lung disease, pulmonary fibrosis, pulmonary edema, and pulmonary hypertension. Clinical applications so far are few, but include subglottic stenosis, tracheomalacia, bronchiomalacia, and emphysema.
Introduction
The main functions of stem/progenitor cells for the airway epithelium are epithelial homeostasis and the repair of defects in the airway wall (Giangreco et al., 2009) . These defects may be due to obstructing tracheal tumors, trauma, or post-intubation tissue reactions that necessitate replacement of tracheal tissue. In addition, the use of tracheo-esophageal silicon rubber speech valves and tracheostoma valves in prosthetic voice rehabilitation is often accompanied by complications that make repair of tissue defects necessary (Ten Hallers et al., 2004) . In many airway diseases such as asthma (Bougault et al., 2009; Burgess, 2009) , chronic obstructive pulmonary disease (COPD) (James and Wenzel, 2007; Tzortzaki and Siafakas, 2009) , obliterative bronchiolitis (a frequent complication of heart-lung transplantation and allogeneic hematopoietic stem cell transplantation) (Qu et al., 2005; Xu et al., 2008; Williams et al., 2009) , and cystic fibrosis (CF) (De Rose, 2002; Hajj et al., 2007) , the airway wall, in particular the airway epithelium, is damaged and subsequently repaired ("remodeled") . Repair of airway epithelium damaged by disease would potentially be a major field where stem/progenitor cells could be used. However, in contrast to some other tissues, such as the gut, the hematopoietic system, skin, and hair follicles, adult stem cells in the lung are still illdefined. Finally, it has to be realized that adult stem cells are not immortal, and show decreasing telomere length with increased age, which may result in an inability to repair damage that therefore becomes irreversible late in life. The possibility to manipulate adult stem cells later in life would potentially improve geriatric care.
An anatomical overview of the airways is shown in Fig. 1 (Fig. 2) . The bronchioli lack cartilage. The epithelium in the major bronchi and proximal bronchioles (Fig. 3a) is a ciliated pseudostratified epithelium, with ciliated columnar cells as the predominant cell type; in the distal bronchioles the epithelium consists of a single cell layer (Fig. 3b) . The ciliated columnar cells reach the basal lamina with slender basal processes (Shebani et al., 2005) . The function of the brush cells of the airway epithelium is not completely known. These cells lack cilia, and may be involved in detoxification, act as a sensor for airway surface liquid, or may have a chemoreceptor function. The pyramid-shaped basal cells rest on the basal lamina but do not reach the airway lumen. The average half-life
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Stem/progenitor cells for airway repair of the ciliated cells has recently been reported to be 6 months in the trachea and 17 months in the lung, which is much longer than previously estimated . This makes the airway epithelium a tissue with a slow turn-over, which is relevant for its repair . Different kinds of secretory cells (goblet cells in the trachea, bronchi and proximal bronchioles, Clara cells in the bronchioles, and neuroendocrine cells in the intrapulmonary airways) comprise around 20% of the bronchial and nasal epithelium and produce airway secretion (fluid and mucus). In addition, the Clara cell secretes Clara cell secretory protein (CCSP), an immunoregulatory protein . The wall of the alveoli consists of squamous alveolar type I and surfactant-producing alveolar type II cells (Fig. 3c ).
In the human, the embryonic lung starts to develop during the fourth week of embryonic development, when a ventral protuberance in the foregut is formed, the respiratory diverticulum ( Fig. 4a) (Larsen, 1993) . This entodermal protuberance is covered by mesodermal splanchnopleure, which will develop first into the 
Stem/progenitor cells for airway repair connective tissue lamina propria, and then into the smooth muscle and cartilage of the airway wall, whereas the blood vessels develop from the aortic arch. On day 26-28, the protuberance splits into two primary bronchial protuberances (the origin of the two lungs), and during the fifth week secondary bronchial protuberances (three on the right side and two on the left side: the lung lobes, Fig. 4b ) are formed. During the sixth week the tertiary bronchial protuberances are formed that will give rise to the lung segments (Fig. 4c) . The protuberances continue to divide during weeks 26-28; the 16th division forms the terminal bronchioles that subsequently give off the respiratory bronchioles and alveolar saccules (week 26) (Fig. 4d) . From about week 32, primitive alveoli are formed. Between week 36 and birth, the alveoli (Fig. 4e ) mature and from parturition on until the age of 8-10 years, new respiratory bronchioles and alveoli are formed. Only at this age the lungs are fully developed (although the lungs retain regenerative capacity at an advanced age, e.g., after surgical resection).
Organ morphogenesis is, in general, controlled by cellcell signaling between the epithelium, the mesenchyme, and the vasculature. In practice, therefore, repair of a defect in the airway wall will require (at a minimum) (progenitors of) epithelial cells, basement membrane, and fibroblasts, as well as cells able to form blood vessels.
As stated above, damage to the airway epithelium may be the result of a number of airway diseases. In addition, extraneous chemicals, e.g., air pollution from traffic or industrial activities, may cause damage to the epithelium. However, even under normal conditions, there has to be a turn-over of the cells of the airway wall. Tissues with a relatively slow turn-over, use the self-renewal of differentiated cells as a strategy for tissue regeneration . In addition, damage to the airway epithelium occurs frequently, e.g., due to components of smoke, air pollution, or to bacterial and viral infection, either from direct effects of these microorganisms or due to the inflammatory reaction that follows infection. Normally, in the case of small lesions, the airway epithelium possesses repair mechanisms that can restore the normal structure. If the damage is more extensive, e.g., in asthmatic patients, the repair process is more extensive, and is called airway remodeling (Folli et al., 2008) . Airway repair appears to be controlled both by bronchial epithelial cells and by endothelial cells of the perfusing bronchial vasculature (Zani et al., 2008) . Of these two cell types, the bronchial epithelial cells have received by far the most attention (Rawlins, 2008; Rawlins et al., 2009 ), whereas little is yet known about the role of the endothelial cells.
Airway progenitor cells/stem cells
In vivo, the basal cells are widely thought to assume the role of progenitor cells (Rock et al., 2009; Snyder et al., 2009) . So far, most experimental studies on lung progenitor cell studies have been performed in murine models. It may be questioned whether this is the best choice for the lung, since there are many structural and physiological differences between murine and human airways (Liu and Engelhardt, 2008) . The pig is a far better animal model for studies of airway physiology than the mouse (Grubb and Boucher, 1999; Cunningham et al., 2002) , but as a large animal it has serious practical drawbacks (e.g., cost of acquisition and maintenance). The airways of the ferret share many similarities with the human airways, with regard to submucosal glands, and fluid transport, in particular CFTR, so the ferret would appear to be a better animal model for airway studies (Sehgal et al., 1996; Wang et al., 2001; Liu and Engelhardt, 2008; Abanses et al., 2009) .
Several potential sources of progenitor cells for airway epithelium have been identified. These can be divided into two groups: (1) endogenous stem/progenitor cells present in the respiratory tract and (2) exogenous stem/progenitor cells derived from other tissues in the body; these latter cells can be transported to the lung, where they can divide and grow.
Endogenous stem/progenitor cells
With regard to the first group, endogenous progenitor cells, one theory has been presented detailing possible stem cell niches in murine airways (Liu and Engelhardt, 2008) (Fig.  1) : (1a) a ductal cell type in the submucosal glands of the proximal trachea, (1b) basal cells in the intercartilaginous Stem-cell niches in the submucosal glands and in the basal layer of the intercartilaginous zones of the lower trachea and bronchi (stem cell types 1a and 1b) were first demonstrated by Borthwick et al. (2001) . These authors found cells expressing high levels of cytokeratin (-5, -14, -18) at these locations in mouse trachea and showed that this cell compartment was rich in bromodeoxyuridine (BrdU) label-retaining cells (LRC) in mice after tracheal damage by intratracheal application of detergent or by having the mice inhale SO 2 . The same result was found after naphthalene-induced tracheal damage (Hong et al., 2004) . Similarly, using a variety of cell proliferation markers (Ki-67, cytokeratin-5 and -14, epidermal growth factor receptor), it was concluded that basal(-like) cells constituted the proliferating cell population in cystic fibrosis (CF) airways (Voynow et al., 2005) . The fact that the basal cells are the primary stem/progenitor cells in the airway was also indicated by Avril-Delplanque et al. (2005) , Coraux et al. (2005), and Hajj et al. (2007) , and confirmed by Rock et al. (2009) , who also developed a method to purify airway basal cells by fluorescenceactivated cell sorting (FACS) , and demonstrated that these cells could self-renew and generate luminal daughters. In conclusion, the evidence appears overwhelming that basal cells in the airway can act as stem/progenitor cells.
The LRCs in the submucosal gland have not yet been characterized, although preliminary data indicate that they may be naphthalene-resistant, Clara cell secretory protein (CCSP)-positive, and associated with calcitonin gene related peptide (CGRP)-expressing cells (Liu and Engelhardt, 2008) . Questions also remain about the epithelial-mesenchymal interactions that are responsible for epithelial invagination, ductal elongation and branching in the submucosal glands. Data from other bud-forming organs indicate that a number of signaling pathways, such as wingless + int-1 (Wnt, e.g., the lymphoid enhancer binding factor (Lef-1)), bone morphogenetic protein (BMP), fibroblast growth factor (FGF), Notch, and Hedgehog, may be involved in the morphogenesis of submucosal glands (Watkins et al., 2003) .
A number of findings have pointed to a possible role of Clara cells as progenitor cells for the bronchial epithelium (Hong et al., 2001; Stripp, 2008; Reynolds and Malkinson, 2010) . A subset of Clara cells in the bronchioles (Clara v -cells) appears to function as local stem/progenitor cells in that region of the airways ). This subset (stem cell type 1c) consisted of LRCs that were CCSP-positive, resistant to naphthalene, could exclude the DNA-binding dye Hoechst 33342, and expressed stemcell antigen (Sca)-1 (Giangreco et al., 2004) . In addition, there is a subset of naphthalene-resistant, CCSP and surfactant protein C double positive, CGRP-negative Clara v cells at the bronchioalveolar duct junction of the adult mouse lung (stem cell type 1d) (Kim et al., 2005) . Finally, a subset of alveolar type II cells (stem cell type 1e) has the ability to replicate and to differentiate into squamous alveolar type I cells after injury (Reddy et al., 2004) . (It should be noted that during embryonic development the alveolar type II cells are formed first in the alveolar lining, and that some of these type II cells undergo terminal differentiation to alveolar type I cells, whereas other type I cells may develop from a pool of epithelial precursor cells in the alveolar lining (Carlsson, 1999) ).
A different theory on stem/progenitor cell populations has been presented by Warburton et al. (2008) , who distinguish (at least) two populations of stem/progenitor cells: (a) the laryno-tracheal portion of the airways, and (b) the distal lung below the first bronchial bifurcation; this population appears to correspond largely to stem cell types 1d (Clara v cells at the junctions of the bronchioles 
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and the alveolar ducts) and 1e (alveolar type II cells) described above. When the alveolar epithelium is damaged, it is likely that at least one progenitor cell per alveolus must be present to achieve rapid repair of the alveolus . After acute oxygen injury, the expression of the enzyme telomerase, which is a marker for progenitor cells, is upregulated in type II alveolar epithelial cells (AEC) during the recovery phase (Driscoll et al., 2000) . AEC positive for telomerase, with reduced levels of E-cadherin, can be isolated by flow cytometry from the lungs of rats during the recovery phase from sublethal hyperoxia, and may be responsible for the repair of the damaged alveolar epithelium (Reddy et al., 2004; Lee et al., 2006) . Progenitor cells can be isolated from normal human adult airways after mechanical and enzymatic digestion. The isolated cells form multicellular spheroids where the cells have alveolar type II or Clara cell features and display both epithelial and mesenchymal cell characteristics (Tesei et al., 2009) . Another CCSP-positive bronchiolar stem/ progenitor cell was described by , with a defining phenotype of CD45(-) CD31(-) CD34(-) Sca-1 (stem cell antigen-1)(low) AF (autofluorescence) (low); these cells could be distinguished from the more abundant pool of Clara cells that were characterized by AF(high), but not by Sca-1 levels, whereas CD34(+) cells did not belong to the airway epithelial cell lineage at all (CD34 cells are mainly found as hematopoietic cells in bone marrow and umbilical cord).
Exogenous stem cells
Examples of the second group, the exogenous stem cells, are: (2a) embryonic stem (ES) cells derived from the inner cell mass of a blastocyst-stage embryo (Coraux et al., 2005) , or (human) amniotic fluid stem cells (Carraro et al., 2008) , (2b) side-population (SP) cells from bone marrow, isolated by virtue of their ability to exclude the DNA-binding dye Hoechst 33342 (MacPherson et al., 2005; MacPherson et al., 2006) , and epithelial stem cells present in bone marrow or in the circulation (Gomperts et al., 2006; Gomperts et al., 2007) , (2c) fat-derived mesenchymal cells , and (2d) induced pluripotent stem (iPS) cells (Takahashi and Yamanaku, 2006; Geoghegan and Byrnes, 2008) .
ES cells propagate readily and generate a great variety of specialized cell types, including (murine and human) airway progenitor cells (Nishimura et al., 2006; Rippon et al., 2006; Wang et al., 2007; Winkler et al., 2008) . However, gaining human ES cells implies destruction of the human embryo, and hence carries obvious ethical problems. In addition, use of ES cells carries the risk of teratoma formation (Cao et al., 2007; Lee et al., 2009 ). These problems are absent from amniotic fluid stem cells that are isolated from discarded amniocentesis specimens (Furth and Atala, 2009 ). These cells can differentiate into specific cell types, and preliminary results have shown that the cells can be injected in the blood stream and then end up in the lung. Since the output of the entire right side of the heart goes to the narrow alveolar capillary bed in the lung, more rigid cells than erythrocytes and leukocytes are easily trapped in the capillary bed. However, transport of the stem cells from the capillaries to the lung parenchyma/airway wall ("homing") is inefficient in the absence of lung damage, and even in the presence of lung damage the efficiency of integration is less than 2% . Hence, improving the efficiency of uptake and integration will be an important prerequisite before clinical studies with exogenous stem/progenitor cells can be successfully carried out. So far, studies on homing of exogenous stem cells in the lung are rare. It has been shown that signals from the damaged lung, such as granulocyte macrophage-colony stimulating factor (GM-CSF), stimulate the bone marrow to release large numbers of mesenchymal cells, that could serve as exogenous stem cells. These cells may make, however, a major contribution to bleomycin-induced pulmonary fibrosis in mice, which is a complication that may have to be taken into account (Liu et al., 2007) .
Adult stem cells from bone marrow have previously been reported to have the potential to give rise to cells of multiple lineage (Krause et al., 2001) , and hence it appeared reasonable to investigate whether they also could give rise to cell lineages in the respiratory tract (MacPherson et al., 2005) . SP-cells are cells with a blood stem cell phenotype, found in small numbers in the bone marrow (Goodell et al., 1996) . As stated above, SP cells are defined by their ability to exclude the DNA-binding dye Hoechst 33342, and therefore also called Hoechst low cells. It was, however, found that putative stem cells from solid tissues also possessed the SP phenotype, and SP cells were isolated from a wide variety of mammalian tissues based on the same dye efflux phenomenon, and in many cases this cell population was shown to contain multipotent stem cells (Challen and Little, 2006) . Indeed, the presence of SP cells in the airways was later demonstrated (Reynolds et al., 2007; Hackett et al., 2008) .
A possible role of exogenous SP cells in lung repair was demonstrated by studies of MacPherson et al. (2005 MacPherson et al. ( , 2006 . SP cells were isolated from the bone marrow of male mice, and seeded on tracheae from female mice, after the epithelium had been removed by treatment with 2% polidocanol. One week after removal of the original epithelium, the epithelium had regrown, and it could be shown that a small proportion of cells had a Y chromosome and hence was of donor origin ("sex mismatch chimera") (MacPherson et al., 2005) . The donor cells had epithelial characteristics as shown by cytokeratin expression, but also hematopoietic characteristics as shown by CD45 expression (MacPherson et al., 2006) . Gomperts et al. (2006) found another population of progenitor epithelial cells in bone marrow and in the circulation in mice. This population was positive for the early epithelial marker cytokeratin 5 (CK5) and the chemokine receptor CXCR4. CK5+ circulating progenitor epithelial cells were found to contribute to reepithelialization of the airway and re-establishment of the pseudostratified epithelium, dependent on the presence of CXCL12 in the tracheal transplant. The keratinocyte growth factor receptor (KGFR) co-localized with a population of CK5+ basal cells in the repairing airway.
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Stem/progenitor cells for airway repair Systemic administration of keratinocyte growth factor (KGF) resulted in a significant increase in mobilization of CK5+ progenitor cells and more rapid repair of the tracheal epithelium. Hence, KGF is an important growth factor for local resident progenitor epithelial cell repair (Gomperts et al., 2007) . Yet another bone marrow-derived cell population capable of repairing injured airways was described by Wong et al. (2009) . This sub-population expressed Claracell secretory protein (CCSP) (like the endogenous stem cells described by Liu and Engelhardt (2008) and mentioned above), type I and type II alveolar markers as well as basal cell markers and epithelial sodium channels (ENaC). The cells could be delivered to the airway intratracheally and homed preferentially to areas with naphthalene-induced lung damage.
Fat-derived stem cells have been used in the repair of bone (Bessa et al., 2008; Betz et al., 2010) , and are regarded as potentially suitable for the repair of soft-tissue defects (Vallée et al., 2009) . Applications to the repair of airway defects are, however, so far few. Adipose-derived stem cells (ASCs) with multilineage differentiation capability were implanted by Suzuki et al. (2008) as part of a bioengineered scaffold into tracheal defects in rats. On day 14 after implantation, a pseudostratified columnar epithelium with well-differentiated ciliated and goblet cells and neovascularization was observed in the rats.
It has been shown to be possible to directly reprogram somatic cells to an embryonic stem cell-like pluripotent state (Takahashi and Yamanaka, 2006; Takahashi et al., 2007) . These induced pluripotent stem (iPS) cells present an important advantage over "real" embryonic stem cells, in that they do not require an embryo to be sacrificed, and that they ultimately will allow autologous transplantation of stem cells to repair damaged tissues (Park et al., 2008) . The reprogramming process requires retroviral transduction with at least three genes: Oct3/4, Sox2 and Klf4 (Geoghegan and Byrnes, 2008; Hong et al., 2009) , and may require suppression of the tumor suppressor genes p53 and p21 (Hong et al., 2009) . Although initially experiments were carried out on mice, it has been shown to be possible to prepare human iPS cells (Hong et al., 2009) . While no direct applications to airway cells have yet been reported, it appears well possible that such applications will become possible in the near future.
Tissue engineering of airway epithelium
Reconstruction of tracheal defects requires in the first place the availability of airway epithelial cells. In addition, it may require the presence of fibroblasts or fibroblastderived substances. Whether fibroblasts themselves or products produced by fibroblasts are required is not yet resolved. Airway epithelial cells should be co-cultured in a system that includes a basal lamina equivalent, extracellular factors of mesenchymal fibroblasts, and the presence of an air-liquid interface system for proliferation and differentiation of the epithelial cells (MacPherson et al., 2005; Pfenninger et al., 2007) . The presence of fibroblasts markedly speeds up the growth of epithelial cells Kobayashi et al., 2007) . However, the effect depends on the source of the fibroblasts. Gingival fibroblasts could induce morphologically and functionally normalized tracheal epithelium (comparable to the epithelium induced by tracheal fibroblasts), whereas nasal and dermal fibroblasts could not (Kobayashi et al., 2007) .
Pioneering work using human tracheal xenografts was carried out in immunodeficient mice (severe combined immunodeficiency (SCID) mice and nude mice), where it was shown that human airway epithelial cells implanted in such conditioned host grafts can regenerate a welldifferentiated and functional human epithelium (Dupuit et al., 2000; Puchelle and Peault, 2000; Escotte et al., 2004) . Native human respiratory epithelial cells grow slowly, so the same group improved on this model by using human airway epithelial cells transduced by a lentivirus vector encoding the enhanced green fluorescent protein (eGFP). After lentiviral transduction the fetal airway epithelial cells rapidly reassembled as three-dimensional spheroid structures, that developed mature cilia, and possessed normal chloride channels and tight junctions; the cells could be kept in culture for (at least) 80 days (Castillon et al., 2004) .
Epithelial cell sheets can be directly transplanted to host tissues without the use of scaffolding or carrier materials. Yang et al. (2006) developed cell sheet engineering using temperature-responsive culture dishes, which allows for the harvest of cultured cells as intact sheets along with their formed extracellular matrix; these sheets can be used for several types of transplantation and surgery, e.g., tracheal replacement and corneal surface transplantation. Oxidant-induced apoptosis of airway epithelial cells, due to activation of caspase-3 and caspase-9, was inhibited by the mucolytic agent carbocisteine (Yoshida et al., 2009) , which may be used to protect transplanted epithelium from cell death. However, the slowness of epithelial cell growth within an animal or on a collagenous artificial trachea (see below) remains a problem. In a series of studies, Nomoto and coworkers therefore optimized methods of culturing airway epithelium. In a first study , isolated rat tracheal epithelial cells were seeded on a collagenous gel that was stratified on a collagenous sponge. The next step was to co-culture tracheal epithelial cells with fibroblasts, which led to the observation that fibroblasts activated epithelial cell proliferation and migration. In coculture with fibroblasts, epithelial cells reconstructed a pseudostratified epithelium, which was composed of ciliated, goblet, and basal cells. Also, a basement membrane was reconstructed below the epithelium . It then was found, that the source of fibroblasts was critical, and that gingival fibroblasts were better suited than nasal and dermal fibroblasts (Kobayashi et al., 2007) . Also Heikal et al. (2008) prepared a tissue-engineered respiratory epithelium construct including autologous (ovine) respiratory epithelial cells, fibroblasts and autologous fibrin, which resulted in the development of cells with immature cilia. Also from studies of physiological airway repair, it is well-known, that the
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Stem/progenitor cells for airway repair interaction between epithelium and mesenchymal elements such as fibroblasts is essential, and an abnormal response of this epithelial-mesenchymal trophic unit has been proposed to be central to the airway pathology and physiology characteristics of asthma (Folli et al., 2008) . Further progress in tissue engineering of airways was obtained by the use of a bipotential collagen scaffold, developed by conjugating a collagen vitrigel membrane to a collagen sponge . suspended isolated rat tracheal epithelial cells in a collagenous gel. This collagenous gel with fibroblasts was layered on a collagenous sponge, and the grafts of this "bioengineered trachea" were implanted into tracheal defects of rats. Already seven to fourteen days after implantation, epithelium had covered most of the defect, and the presence of fibroblasts had a positive effect on epithelial growth, even though the fibroblasts disappeared in the end.
The fact that fibroblasts had a positive effect on airway epithelial cell growth emphasizes the fact that the airway wall is not a simple structure, and that epithelialmesenchymal interactions are important. A complicated system was proposed by Walles et al. (2004) , who used 10-to 15-cm-long acellularized pig jejunal segments with their own vascular pedicle. Autologous costal chondrocytes, smooth muscle cells, and respiratory epithelium and endothelial progenitor cells were cultured in vitro and disseminated on this matrix. The endothelial progenitor cells re-endothelialized the matrix and the vascularized scaffold was seeded with smooth muscle cells and viable ciliated respiratory epithelium. Chondrocyte growth and production of extracellular cartilaginous matrix was observed as soon as 2 weeks after their culture.
Tissue engineering of trachea
To repair larger defects, it may be necessary to grow the airway epithelium (plus fibroblasts) on a sturdy, solid, biocompatible substrate, e.g., polymer-coated wires (Servetnyk et al., 2006) . Repair of larger defects may also make it necessary to use cartilage implants, and this has been investigated primarily for use in laryngotracheal reconstruction (LTR) after stenosis. In a series of studies by Kojima and coworkers, chondrocytes and fibroblasts were isolated and seeded onto separate non-woven meshes of polyglycolic acid. The chondrocyte-seeded mesh was wound around a helical template and then covered with the fibroblast-seeded mesh. Gross morphology and tissue morphology of tissue-engineered tracheas (TET) was similar to that of native tracheas. Collagen and cell contents in TET were elevated compared with that of normal tracheas, whereas proteoglycan content was less than in normal tracheas (Kojima et al., 2002; Kojima et al., 2003a) . Kojima et al. (2003b) showed that the properties of tissueengineered trachea using nasal chondrocytes were similar to that obtained using tracheal chondrocytes, which has the advantage of facilitating use of an easily obtainable autologous source of chondrocytes for repair of segmental tracheal defects. A composite engineered cylindrical tracheal equivalent constructed from autologous tissue could be lined with nasal epithelial cells in a nude-mouse model. However, some problems with the mechanical stability of the tracheal implant were reported (Kojima and Vacanti, 2004) . Weidenbecher et al. (2007) used Hyalograft C combined with autologous chondrocytes to engineer cartilage grafts for LTR in rabbits. However, all tissueengineered grafts and empty scaffolds revealed marked signs of an unspecific foreign body reaction, leading to a complete degradation of the neocartilage, whether implanted para-or intralaryngeally. This group also implanted autologous neotracheal constructs in the abdomen of rabbits, using scaffold-free cartilage sheets made of auricular chondrocytes. A muscle flap raised from the external abdominal oblique muscle and the engineered cartilage were wrapped around a silicone stent to fabricate a vascularized neotrachea in vivo. It was found that scaffold-free engineered cartilage can successfully fabricate a well-vascularized, autologous neotrachea (Weidenbecher et al., 2008; Weidenbecher et al., 2009; Gilpin et al., 2010) .
Recent studies in animals have pointed out the usefulness of combining epithelial stem/progenitor cells and mesenchymal stem cell-derived chondrocytes to repair airway defects (Baiguero et al., 2010; Go et al., 2010) . In order to repair tracheal stenosis, Komura et al. (2008) designed an engineered tracheal graft from a biodegradable scaffold using chondrocyes for rabbit auricular cartilage. The cells were seeded on a scaffold consisting of collagen, a polyglycolic acid mesh, and an L-lactide/ε-caprolactone mesh; basic fibroblast growth factor was released into the graft from gelatin sponges.
A different approach was taken by Yamashita et al. (2007) who regenerated tracheal epithelium in an experimentally-induced defect in canine trachea. A polypropylene and collagen scaffold preclotted with peripheral blood was inserted into the defect, and this resulted after 8-12 months in a regenerated mucosa with ciliated epithelium and capillaries, as well as newly formed cartilage.
Developmental signaling molecules of relevance for tissue engineering
It is evident that knowledge about the development of the respiratory system in the embryo is relevant for tissue engineering to repair the airways in the adult, particularly details on the regulation of cell proliferation and differentiation. As stated above, the lung starts to develop as a ventral protuberance in the foregut, and separation of this protuberance (the future larynx and trachea) from the foregut (the future esophagus, stomach and duodenum) is a necessary step for the subsequent separation of the foregut tube into trachea and esophagus. Defects in foregut morphogenesis underlie the human birth defects known as esophageal atresia and tracheo-esophageal fistula. Que et al. (2006) showed that most mouse embryos homozygous null for Nog, the gene encoding noggin, a bone morphogenetic protein (Bmp) antagonist, have esophageal atresia or tracheo-esophageal fistulas, as well as defects in lung branching, but that these abnormalities
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can be rescued by reducing the gene dose of Bmp4 by 50%. Hence, normal foregut morphogenesis requires that the level of Bmp4 activity is carefully controlled by means of antagonists such as noggin. Several gene factors may influence the process of airway epithelial growth. The tumor suppressor gene Pten, which is mutated in many human cancers, appears to be essential for the homeostasis of bronchioalveolar stem cells and hence for normal lung morphogenesis and the prevention of lung carcinogenesis (Yanagi et al., 2007) . Deletion of this gene caused inhibition of the differentiation of various lung epithelial cell lines, with decreased numbers of terminally differentiated cells (Tiozzo et al., 2009) . Another tumor suppressor gene, p63, related to the p53 gene, is present mainly in the basal layer of the developing trachea (and esophagus), but decreases towards the more superficial cells (Daniely et al., 2004) ; this gene appears in general to be involved in the development of stratified epithelia (Koster et al., 2004; Senoo et al., 2007) . In contrast to basal cells, ciliated cells express the HNF-3/ forkhead homologue-4 (HFH-4), a transcription factor of the winged-helix/forkhead family (Blatt et al., 1999; Tichelaar et al., 1999) .
The Sox2 gene is important for the branching of the airways; it appears that downregulation of this gene is required for branching to take place (Gontan et al., 2008) . Investigations of the significance of the Sox2 gene (Que et al., 2009) were carried out on mutants with a conditionally deleted Sox2 gene in the ventral epithelial domain of the early anterior foregut, which gives rise to the future trachea and lung buds. All mutants died of respiratory distress at birth, and most had a short trachea, which means that the primary budding site of the lung shifted anteriorly. Conditional deletion of Sox2 was also important in the maintenance of adult epithelium, since epithelial cells lacking Sox2 showed a reduced capacity to proliferate in culture and to repair after injury in vivo. Sox17, a gene required for early endoderm formation, reduced the expression of transforming growth factor (TGF)-β cell cycle inhibitors, and hence activated the cell cycle, and reinitiated multipotent progenitor cell behavior in mature lung cells (Lange et al., 2009) . The Notch gene is instrumental in the differentiation of cells in the proximal airways, silencing the ciliated program in those cells that will differentiate into secretory cells (Tsao et al., 2009 ).
The connective tissue compartment
The important role of tracheal mesenchymal cells for the growth of the respiratory epithelium has been discussed above. During embryonic development, mesenchyme and vascular smooth muscle develop from mesothelium . As stated previously, in the bioengineered lung, mesenchyme cells can be obtained from a variety of fibroblast sources, but tracheal mesenchyme cells can also be isolated from the lungs of premature infants undergoing mechanical ventilation (Hennrick et al., 2007) . In addition to endogenous mesenchymal cells, also exogenous mesenchymal cells, such as bone marrow-derived mesenchymal stem cells (BMSCs) can be used (Van Haaften et al., 2009) . In animal experiments (rats), it could be shown, that BMSCs developed characteristics of type II alveolar epithelial cells (AEC2) when co-cultured with lung tissue, and were preferentially attracted towards oxygen-damaged lung vs normal lung. In vivo, intratracheal delivery of BMSCs in newborn rats improved survival of the animals while attenuating alveolar and lung vascular injury and pulmonary hypertension. However, it was doubtful if this was due to BMSCs acting as stem/ progenitor cells, because of their small numbers; a more likely explanation of the effect was felt to be a paracrine activity of the BMSCs (Van Haaften et al., 2009) .
Since airway mesodermal cells, such as myofibroblasts and airway smooth muscle cells, contribute to the pathology of asthma by excessive proliferation, it was investigated whether mesenchymal cells from asthmatics would be more suitable for use in tracheal reconstruction than mesenchymal cells from healthy donors; this was not found to be the case (Ward et al., 2008) .
Apart from their importance for epithelial growth, airway mesenchymal cells also have a wider significance. The administration of mesenchymal stem cells (MSCs) has been proposed for the treatment of pulmonary hypertension. Baber et al. (2007) studied the effect of intratracheal administration of rat MSCs (rMSCs) on monocrotaline-induced pulmonary hypertension and impaired endothelium-dependent responses. Intratracheal injection of rMSCs after administration of monocrotaline attenuated the rise in pulmonary arterial pressure and pulmonary vascular resistance, restored pulmonary responses to acetylcholine toward normal values, and decreased the right ventricular hypertrophy induced by monocrotaline. Transplanted rMSCs were found widespread in the lung parenchyma surrounding the airways in monocrotaline-treated rats and retained markers specific for endothelial and smooth muscle phenotypes, but were not detected in the wall of pulmonary vessels.
Treatment of experimental animals with bleomycin or alcohol is used as an animal model for fibrosis. In rats treated with bleomycin, it was investigated whether MSC engraftment could protect the lungs against bleomycininduced injury (Zhao et al., 2008) . Some MSCs positive for pan-cytokeratin staining, an indicator of alveolar epithelial cells, were present in the injured lung tissue. Bleomycin injection increased the content of hydroxyproline in lung tissue, as well as laminin and hyaluronan in bronchoalveolar lavage fluid, markers for lung injury and fibrosis. These effects were attenuated by MSC treatment. Lung fibrosis also is associated with increased synthesis of transforming growth factor-β1 (TGF-β1), platelet-derived growth factor (PDGF)-α, PDGF-β, and insulin-like growth factor (IGF)-I. Also this effect of bleomycin was significantly decreased by MSC treatment (Zhao et al., 2008) .
Clinical applications
Concurrent with the ongoing search for stem cells that can be applied to human treatment, precise delivery and homing (to the site of the disease) must be ensured for
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Stem/progenitor cells for airway repair successful therapy. Stem cells can safely be instilled via the trachea. This involves a skin incision below the larynx, opening of the tracheal lumen, and caudal insertion of a cannula into and along the tracheal lumen, and injection of a stem cell vehicle mixture into the airways. The airway epithelium will confine the stem cells initially to the airway lumen, and subsequently, lung expansion and negative pressure during inhalation may assist in stem cell integration in the epithelium (Peter, 2007) . In a murine model of epithelial airway injury, up to about 5% of the injected stem cells survived, but survival was drastically reduced when the airway epithelium was intact (Leblond et al., 2009 ). There will certainly also be obstacles involving physiologic barriers such as mucus and airwaysurface or alveolar liquid (Roy and Vij, 2010) . A common feature of lung disorders with poor treatment options, including emphysema, is a failure to initiate a repair process of the alveolar epithelium. As stated previously, several putative stem cell niches in the lung thought to be involved in lung homeostasis have been described. (Liu and Engelhardt, 2008) . However, under pathophysiological conditions resident stem cell niches in the lung thought to be involved in lung homeostasis are unable to recover damaged alveolar epithelium, in particular in emphysema. (Emphysema is a subtype of COPD, defined as dilatation and destruction of lung tissue distal to the terminal bronchiole). Recently, it has been shown that all-trans-retinoic acid (ATRA), an analogue of vitamin A, has a potential therapeutic effect on various resident lung progenitor cells (Lenssen and Stolk, 2007) . Experiments on rat and mice models of emphysema have shown that ATRA inhibited progression of airway obstruction (Tepper et al., 2000) and promoted lung regeneration after injury (Ishizawa et al., 2004) . Retinoic acid reduced the damage induced by elastase to cultured airway epithelial cells (cell lines and primary cultures) (Nakajoh et al., 2003) . Elastase treatment of laboratory animals is an established model in experimental studies of emphysema (Hayes et al., 1975; Kaplan et al., 1973) . The first study with retinoic acid on humans, however, failed to show any positive effects on the emphysema, but did show mild negative side-effects (including skin changes, transient headache, hyperlipidemia, transaminites, and musculoskeletal pains) (Mao et al., 2002) . The absence of positive effects was confirmed in a later study (Roth et al., 2006) . Nonetheless, a further clinical study is in progress (Lenssen and Stolk, 2007) . However, additional studies on mice have shown strain-specific differences in the response to retinoic acid (Stinchcombe and Maden, 2008) . The potential effect of retinoic acid on emphysema is hence at the moment, unclear.
For a number of serious airway diseases, stem/ progenitor cell therapy has been suggested as a possible cure. For none of these diseases there is yet experimental support that stem/progenitor cells would be helpful. The prime disease mentioned in this respect is cystic fibrosis (Olsson et al., 2007; Weiss, 2008) , but also acute respiratory distress syndrome (ARDS) (Jiang and Li, 2009) , COPD Ohnishi and Nagaya, 2008) , pulmonary fibrosis, pulmonary edema (Olsson et al., 2007) , and pulmonary hypertension (Sueblinvong and Weiss, 2009 ). It has also been suggested to use stem/ progenitor cells to promote perinatal lung growth (Roszell et al., 2009) . Chen et al. (2008) reported a successful attempt at transplanting stem cells in two patients with mucopolysaccharidosis (MPS), a lysosomal storage disease caused by the absence or malfunctioning of the enzymes needed to break down glycosaminoglycans, and commonly associated with obstructive airway disease and obstructive sleep apnea (Yeung et al., 2009 ). The two patients were (at the time of transplantation) a 23-month MPS type IH patient and an 18-month old MPS type VI patient. Surprisingly, the authors also reported that the cornea, which normally is clouded in MPS patients, became clear and that the patient's heart condition improved.
Subglottic stenosis is characterized by the obliteration of the tracheal lumen due to excessive formation of connective tissue. Tracheal injury triggers the early production of transforming growth factor-beta1 (TGF-β1), a factor implicated in fibroproliferative disorders. TGF-β1 stimulates the transformation of tracheal fibroblasts into myofibroblasts with increased matrix production and scar contraction (Jarmuz et al., 2004) . Such a condition is, as stated above, a prime example where repair of the airway by stem cells could be used. Omori et al. (2008) developed a tissue scaffold made from a mesh tube covered by collagen sponge, which was implanted to repair the larynx and trachea in 4 patients (1 with subglottic stenosis and 3 with thyroid cancer), where the cartilage of the cervical trachea and laryngeal cartilages were resected and reconstructed by use of the scaffold. This was reported to result in a well-epithelialized airway lumen without any obstruction.
The most interesting series of studies on bioengineered trachea was initialized by Macchiarini et al. (2004) , who prepared a bioartificial patch starting from muscle cells and fibroblasts isolated from a biopsy obtained from the patient (i.e., the future recipient of the transplant). These cells were seeded onto a collagen network obtained from a decellularized porcine jejunal segment (the porcine tissue was gradually replaced by autologous connective tissue) . The thus obtained patch was after some weeks of culture transplanted to the patient. After the transplantation, the patch was reseeded with the patient's own cliliated respiratory epithelium. The first human tissue-engineered trachea replacement was performed by Macchiarini et al. (2008) , who removed cells and thereby major histocompatibility complex (MHC) antigens from a tracheal segment of a deceased human donor (a 51-year old female), which was then readily colonised by epithelial cells and mesenchymal stem-cellderived chondrocytes that had been cultured from cells taken from the recipient (a 30-year old woman with endstage bronchomalacia). This graft was then used to replace the recipient's left main bronchus. The graft immediately provided the recipient with a functional airway, improved her quality of life, and had a normal appearance and mechanical properties at 4 months. Since this was transplantation with autologous epithelial cells and
Stem/progenitor cells for airway repair chondrocytes, the patient had no anti-donor antibodies and did not need immunosuppressive drugs. At 18 months after the surgery, the patient was reported to lead a near-normal life without immunosuppression . Finally, it has been proposed that since chronic lung diseases, such as obliterative bronchiolitis, COPD, and asthma are characterized by epithelial and mesenchymal remodeling (with as main features chronic injury to the airway epithelium, decreased number of Clara cells, goblet cell hyperplasia, mucous cell metaplasia, basement membrane thickening, and smooth muscle hypertrophy), a more thorough understanding of the role of stem/ progenitor cells in airway biology could yield important insights into these chronic disease processes .
Conclusion
In theory, stem cells can be used to repair defects in the airways, and this could be used to treat airway diseases varying from common (COPD, pulmonary edema, repair of tumor-connected defects) to less common (ARDS, bronchomalacia, CF, pulmonary hypertension). Given the fact that (chronic) airway diseases occupy four of the topten places in the list of global causes of death (www.who.int /mediacentre/factsheets/fs310), the importance of finding a cure for these diseases cannot be overestimated. Stem cell therapy provides a potentially novel approach to this problem, and deserves to be seriously explored. There are many potential sources for suitable stem cells, each with their own advantages and disadvantages: some can be isolated from the lung, and thus resemble closely the cell type needed for repair, but here the problem may be to obtain a sufficient number of stem cells. Other stem cells can more easily, and in greater quantity, be obtained from other tissues, such as bone marrow or adipose tissue, but steps are needed to "convert" these cells to airway cells. Cells suitable for transplantation can be isolated from the patient that is to be treated (e.g., Macchiarini et al., 2008) , which is a definite advantage, because it avoids the need for immunosuppressive drugs. It is also clear that much work is needed before stem cell therapy in respiratory medicine can be done in practice. "Homing" of the stem cells that act as a replacement still is a problem, because it appears to require extensive epithelial damage of the cells that have to be replaced. At the moment, practical results are scarce, but the interest in this field is growing.
